Saihe Biotechnology secures tens of millions in Angel+ funding to advance innovative radiopharmaceutical R&D and clinical trials

Saihe Biotechnology announced that it has completed an Angel+ funding round totaling tens of millions of RMB. The round was led by existing shareholder FIRHealth Capital, with participation from Longtai Investment. The proceeds will be used to accelerate the clinical trials of Saihe Biotechnology's core pipeline and to recruit specialized talent for research and development of underlying innovative technologies in radiopharmaceuticals, aiming to develop potent and specific novel cancer therapies for the benefit of cancer patients worldwide.

Cancer poses a major threat to human health, with nearly 10 million people dying from the disease globally each year. Targeted alpha-particle therapy delivers radioactive isotopes precisely to cancer tissues via targeting moieties. It offers significant advantages including high potency, specificity, and the integration of diagnosis and treatment, enabling a "see and treat" approach. Considered a next-generation therapy following immunotherapy and cell therapy, it is a major research focus in the field of cancer treatment both in China and internationally.